Evolus, Inc. (NASDAQ:EOLS) Insider Sells $33,409.95 in Stock

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 3,385 shares of the company’s stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $9.87, for a total value of $33,409.95. Following the completion of the transaction, the insider now directly owns 359,082 shares of the company’s stock, valued at $3,544,139.34. This represents a 0.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Rui Avelar also recently made the following trade(s):

• On Tuesday, March 18th, Rui Avelar sold 27,904 shares of Evolus stock. The shares were sold at an average price of $13.26, for a total value of $370,007.04.

Evolus Price Performance

Evolus stock opened at $10.00 on Friday. The stock has a market capitalization of $644.76 million, a price-to-earnings ratio of -10.99 and a beta of 1.11. Evolus, Inc. has a 52-week low of $8.67 and a 52-week high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The stock’s 50 day moving average price is $11.38 and its two-hundred day moving average price is $12.41.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. AlphaQuest LLC acquired a new stake in Evolus in the first quarter worth $39,000. State of Wyoming boosted its position in shares of Evolus by 988.1% during the 1st quarter. State of Wyoming now owns 3,754 shares of the company’s stock worth $45,000 after purchasing an additional 3,409 shares in the last quarter. KBC Group NV acquired a new stake in shares of Evolus in the 4th quarter valued at about $49,000. IFP Advisors Inc increased its position in Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after buying an additional 4,709 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in Evolus during the 4th quarter worth approximately $106,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on EOLS shares. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. Barclays increased their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. BTIG Research initiated coverage on shares of Evolus in a report on Thursday, April 17th. They issued a “buy” rating and a $21.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Thursday, May 8th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Evolus presently has an average rating of “Buy” and an average target price of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.